F19.95
Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder
Clinical Classification Guidelines
Medical Intelligence & Overview
ICD-10 code F19.95 pertains to cases where an individual has used psychoactive substances in an unspecified manner and is experiencing a psychotic disorder induced by such substances. Psychoactive substances include drugs that alter brain function, affecting perception, mood, consciousness, cognition, or behavior. When these substances lead to serious mental health issues like hallucinations or delusions, a psychotic disorder can develop. This code is typically used when the specific substance is not identified or documented, but there is evidence of substance use and psychosis related to that use. The condition requires careful assessment to understand the severity and specific features of the psychotic episode.
Causes & Symptoms
Clinical Causes: Use of psychoactive substances such as stimulants (amphetamines, cocaine), hallucinogens (LSD, psilocybin), or depressants. Ingestion of substances in higher doses or for prolonged periods. Combining different psychoactive drugs, which can increase the risk of adverse mental health effects. Underlying mental health vulnerabilities that may predispose an individual to substance-induced psychosis. Sudden cessation or withdrawal from certain psychoactive substances.
Key Symptoms: Hallucinations, particularly auditory or visual. Delusional beliefs, including paranoia or irrational fears. Disorganized thinking or speech patterns. Agitation, restlessness, or hyperactivity. Emotional disturbances such as euphoria, depression, or agitation. Physical signs like dilated pupils, rapid heartbeat, or sweating. Impaired reality testing, difficulty distinguishing between what is real or imaginary. Potential confusion or disorientation.
Diagnostic & Treatment
Diagnosis Path: Diagnosis involves a comprehensive clinical assessment by a healthcare professional, including patient history, physical examination, and mental health evaluation. Important aspects include identifying recent or current psychoactive substance use, duration and pattern of use, and the presence of psychotic symptoms. Laboratory tests, such as blood or urine tests, may be used to detect specific substances. Mental status examinations help differentiate substance-induced psychosis from primary psychotic disorders like schizophrenia. Additional diagnostic criteria, based on the DSM-5 or ICD standards, guide the clinician in establishing an accurate diagnosis.
Treatment Protocols: Treatment strategies focus on managing both the substance use and the psychotic symptoms. Approaches may include: - Pharmacological interventions, such as antipsychotic medications, to control psychotic symptoms. - Supportive care and monitoring in a safe environment. - Abstinence from psychoactive substances, often requiring detoxification programs. - Psychotherapy, including cognitive-behavioral therapy (CBT), to address underlying issues and prevent relapse. - Social support and rehabilitative services to promote recovery and reduce substance dependence. - Educational and psycho-social interventions to inform about the risks associated with psychoactive substances. It is crucial for treatment plans to be tailored to each individual's needs, considering the specific substances used and the severity of symptoms.
Clinical Advice & FAQs
Billing Guidance
Is F19.95 a billable ICD-10 code?
Yes, F19.95 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report F19.95?
Clinical documentation must specify the nature of Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder and any associated comorbidities for accurate reporting.
Cite this Clinical Reference